Market Overview

Stocks Hitting 52-Week Highs

Share:
Related MDVN
Benzinga's M&A Chatter for Monday August 24, 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin
Medivation to Gain Global Rights to BioMarin's Talazoparib (Zacks)
Related TEVA
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
Eli Lilly's Alimta Patent Upheld by U.S. District Court (Zacks)

Medivation (NASDAQ: MDVN) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00.

Teva Pharmaceutical Industries (NYSE: TEVA) shares reached a new 52-week high of $45.60 after the company reported the FDA approval of three-times-a-week COPAXONE 40mg/mL.

CBRE Group (NYSE: CBG) shares jumped 1.54% to touch a new 52-week high of $27.06. CBRE Group is expected release its Q4 financial results on February 5, 2014.

Jones Lang LaSalle (NYSE: JLL) shares surged 5.69% to reach a new 52-week high of $112.36 after the company reported stronger-than-expected Q4 results.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

 

Related Articles (CBG + JLL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters